GlassScriptPhysician profile
Bridget K Carlson
NPI 1639832975
$4,929.12
in general payments reported to CMS, 2019-2025
44 companies · $2,325 in 2025
The $2,325 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.44 · 2022: $341 · 2023: $677 · 2024: $1,564 · 2025: $2,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,566.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $603.28 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $587.20 | 2022-2025 | |
| Lilly USA, LLC | $269.11 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Microtransponder, INC. | $246.04 | 2024 | |
| Biogen, INC. | $227.88 | 2023-2025 | Tysabri, Vumerity, Avonex |
| Jazz Pharmaceuticals INC. | $227.67 | 2022-2025 | |
| Pfizer INC. | $218.17 | 2023-2025 | |
| Axsome Therapeutics, INC. | $213.81 | 2023-2025 | Sunosi, Symbravo |
| Genentech USA, INC. | $202.86 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $181.12 | 2022-2025 | Austedo Xr, Ajovy |
| Azurity Pharmaceuticals, INC. | $160.42 | 2023-2025 | Horizant, Horizant |
| Takeda Pharmaceuticals U.S.A., INC. | $132.58 | 2024-2025 | Hyqvia |
| Lundbeck LLC | $117.60 | 2022-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $111.42 | 2024-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $100.94 | 2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.